Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Hikma Pharmaceuticals subsidiary West-Ward Pharmaceuticals' ANDA for fluticasone propionate/0.05mg per spray and Perrigo is shipping the generic equivalent of Flonase Allergy Relief to retailers and distributors.

Advertisement

Related Content

OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule
Supplement, Drug Co-Packaging Potential Could Be Clipped In FDA Proposed Rule
Perrigo's Return To OTC Roots Restoring Investor Confidence
GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS108360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel